We use cookies for a better user experience. Read our Privacy Policy
I Agree
Radiopharmaceutical Theranostics Market Forecast Report, 2021-2031
The emergence of the COVID-19 outbreak has become a threat to the global health. This has compelled stakeholders in the radiopharmaceutical theranostics market to increase their R&D in nuclear medicine techniques that are found to be useful for functioning imaging of physiological processes at the cellular or molecular level. Companies are expanding in treatment approaches based on targeted delivery of therapeutic radionuclides.
Advancements in radiolabeling methods can significantly improve the accessibility of radiopharmaceuticals for in vivo molecular imaging or targeted radionuclide therapy. Such trends are anticipated to boost the growth of the radiopharmaceutical theranostics market during the ongoing pandemic. Stakeholders are expected to collaborate with researchers to describe how radio-labeled analogs of nuclear medicine could facilitate antiviral drug development.
To know the scope of our report Get a Sample on Radiopharmaceutical Theranostics Market
Nuclear medicines have led to the popularity of radiopharmaceuticals that carry the ability to destroy specific diseased cells with high-energy-emitting radionuclides. However, it has been found that integrating positron emission tomography (PET) and MRI (magnetic resonance imaging) modalities is challenging, as there is a possibility for interference between both the modalities. Hence, stakeholders are integrating PET detectors and MR scanners to obtain PET and MR images simultaneously.
Companies in the radiopharmaceutical theranostics market are increasing the availability of radioactive medicines through oral, intravenous, and interstitial route to diagnose malignancy. The high prevalence of cancer is acting as a key growth driver of the radiopharmaceutical theranostics market, as radioactive medicines have the ability to destroy cancerous cells by emitting radiation when it reaches the target cell.
Get a glimpse of the in-depth analysis through our Report Brochure
Radiopharmaceuticals are generating major oncology deals globally. A €182 Mn IPO was announced in June 2020, where the U.S.-based Fusion Pharma was recently recruited by pharma giant AstraZeneca to co-develop radiotherapies for cancer. Apart from major investments taking place in the U.S., stakeholders in the radiopharmaceutical theranostics market are witnessing a high level of interest and activity in Europe and the Far East. In September 2020, the Belgian company Camel-IDS rebranded as Precirix has advanced its lead candidate radiopharmaceutical into phase I/II.
Since responses with radiopharmaceutical agents typically do not require many months of therapy, it is being preferred over chemotherapy and immunotherapy. Radioactive iodine is emerging as the gold standard to image the spread of thyroid tumors.
In a research presented at the Society of Nuclear Medicine and Molecular Imaging’s 2021 Virtual Annual Meeting, a novel cancer treatment approach is being publicized for utilizing the Cerenkov radiation energy to target and destroy cancer cells more effectively. Companies in the radiopharmaceutical theranostics market are taking cues from such insights to use light from decaying radiopharmaceuticals, known as Cerenkov luminescence, as an energy source to activate semiconducting polymer nanoparticles that kill cancer cells.
Cerenkov luminescence is being proposed as an internal energy source for cancer therapy in the radiopharmaceutical theranostics market. This light source can be amplified with semiconducting polymers, which greatly increases its potential to target and destroy cancer cells.
The Nuclear Medicine Oncology and Radiotherapy Centre (INOR) in Abbottabad and the Institute of Nuclear Medicine and Oncology (INMOL) in Lahore, Pakistan, are now developing novel radiopharmaceuticals for use in theranostic procedures, using equipment and training provided through the IAEA’s technical cooperation (TC) program. This is evident since non-communicable diseases such as cardiac dysfunction, cancer, and neurological disorders are concerning national health authorities in the country.
Since the incidence of non-communicable diseases is estimated to double in the upcoming years in Pakistan, theranostic interventions are gaining popularity for accurate diagnosis of cancer in the radiopharmaceutical theranostics market.
Expanding operations in future? To get the perfect launch ask for a custom report
Analysts’ Viewpoint
Based on the continuing threat by the ongoing coronaviruses pandemic and other pathogens, it is anticipated that nuclear medicines hold strong potential in the development of antiviral drug and treatment. The radiopharmaceutical theranostics market is projected to expand at a robust CAGR of 11% from 2021 to 2031. The photodynamic therapy helps activate nanomaterials for the cancer therapy. However, this technique is limited by the ability of external light to penetrate tissues. Hence, companies should increase their R&D in Cerenkov luminescence, which is spontaneously produced from certain radiopharmaceuticals as the decay in the body. This technique has been proposed as an internal energy source for the cancer therapy.
Radiopharmaceutical Theranostics Market – Segmentation
TMR’s study on the global radiopharmaceutical theranostics market includes information divided into six segments: radioisotope, application, source, end user, approach, and region. Changing industry trends and other crucial market dynamics associated with these segments of the global radiopharmaceutical theranostics market are discussed in detail.
| Radioisotope |
|
| Application |
|
| Source |
|
| End User |
|
| Approach |
|
| Region |
|
Interested in this report?
Get a FREE Brochure now!
*Get Brochure Report (PDF) sent to your email within minutes
Radiopharmaceutical theranostics market to reach valuation of US$ 3.9 Bn by 2031
Radiopharmaceutical theranostics market is projected to expand at a CAGR of 11% from 2021 to 2031
Radiopharmaceutical theranostics market is driven by increase in therapeutic applications, public awareness, usage of hybrid imaging
The lutetium (Lu) 177 segment dominated the global radiopharmaceutical theranostics market in 2020 and the trend is anticipated to continue during the forecast period
Key players operating in the global market include Nihon Medi-Physics, ITM Isotopen Technologien München AG, Advanced Accelerator Applications, Telix Pharmaceuticals, GE Healthcare
1. Preface
1.1. Market Definition and Scope
1.2. Market Segmentation
1.3. Key Research Objectives
1.4. Research Highlights
2. Assumptions and Research Methodology
3. Executive Summary: Global Radiopharmaceutical Theranostics Market
4. Market Overview
4.1. Introduction
4.1.1. Radioisotope Market Definition
4.1.2. Industry Evolution / Developments
4.2. Overview
4.3. Market Dynamics
4.3.1. Drivers
4.3.2. Restraints
4.3.3. Opportunities
4.4. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, 2017–2031
4.4.1. Market Revenue Projections (US$ Mn)
5. Key Insights
5.1. Overview of Radiopharmaceuticals market
5.2. FDA Approved Radiopharmaceuticals Products
5.3. Overview of Radiopharamceutical Diagnostic Market
5.4. Overview of Radiopharamceutical Therapy Market
5.5. Regulatory Scenario
5.6. Current and Future Radiopharmaceutical Theranostics Pairs
5.7. COVID-19 Impact Analysis
6. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Radioisotope
6.1. Introduction & Definition
6.2. Key Findings / Developments
6.3. Market Value Forecast, by Radioisotope, 2017–2031
6.3.1. Technetium-99
6.3.2. Gallium-68
6.3.3. Iodine-131
6.3.4. Iodine-123
6.3.5. 18F
6.3.6. Y-90
6.3.7. Lutetium (Lu) 177
6.3.8. Copper (Cu) 67
6.3.9. Copper (Cu) 64
6.3.10. Others
6.4. Market Attractiveness Analysis, by Radioisotope
7. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Application
7.1. Introduction & Definition
7.2. Key Findings / Developments
7.3. Market Value Forecast, by Application, 2017–2031
7.3.1. Oncology
7.3.2. Cardiology
7.3.3. Others
7.4. Market Attractiveness Analysis, by Application
8. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Source
8.1. Introduction & Definition
8.2. Key Findings / Developments
8.3. Market Value Forecast, by Source, 2017–2031
8.3.1. Nuclear Reactors
8.3.2. Cyclotrons
8.4. Market Attractiveness Analysis, by Source
9. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Approach
9.1. Introduction & Definition
9.2. Key Findings / Developments
9.3. Market Value Forecast, by Approach, 2017–2031
9.3.1. Targeted Therapeutic (Rx)
9.3.2. Companion Diagnostic (DX)
9.4. Market Attractiveness Analysis, by Approach
10. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by End-user
10.1. Introduction & Definition
10.2. Key Findings / Developments
10.3. Market Value Forecast, by End-user, 2017–2031
10.3.1. Hospitals
10.3.2. Academic & Research Institutes
10.3.3. Others
10.4. Market Attractiveness Analysis, by End-user
11. Global Radiopharmaceutical Theranostics Market Analysis and Forecast, by Region
11.1. Key Findings
11.2. Market Value Forecast, by Region
11.2.1. North America
11.2.2. Europe
11.2.3. Asia Pacific
11.2.4. Latin America
11.2.5. Middle East & Africa
11.3. Market Attractiveness Analysis, by Country/Region
12. North America Radiopharmaceutical Theranostics Market Analysis and Forecast
12.1. Introduction
12.1.1. Key Findings
12.2. Market Value Forecast, by Radioisotope, 2017–2031
12.2.1. Technetium-99
12.2.2. Gallium-68
12.2.3. Iodine-131
12.2.4. Iodine-123
12.2.5. 18F
12.2.6. Y-90
12.2.7. Lutetium (Lu) 177
12.2.8. Copper (Cu) 67
12.2.9. Copper (Cu) 64
12.2.10. Others
12.3. Market Value Forecast, by Application, 2017–2031
12.3.1. Oncology
12.3.2. Cardiology
12.3.3. Others
12.4. Market Value Forecast, by Source, 2017–2031
12.4.1. Nuclear Reactors
12.4.2. Cyclotrons
12.5. Market Value Forecast, by Approach, 2017–2031
12.5.1. Targeted Therapeutic (Rx)
12.5.2. Companion Diagnostic (DX)
12.6. Market Value Forecast, by End-user, 2017–2031
12.6.1. Hospitals
12.6.2. Academic & Research Institutes
12.6.3. Others
12.7. Market Value Forecast, by Country, 2017–2031
12.7.1. U.S.
12.7.2. Canada
12.8. Market Attractiveness Analysis
12.8.1. By Radioisotope
12.8.2. By Application
12.8.3. By Source
12.8.4. By Approach
12.8.5. By End-user
12.8.6. By Country
13. Europe Radiopharmaceutical Theranostics Market Analysis and Forecast
13.1. Introduction
13.1.1. Key Findings
13.2. Market Value Forecast, by Radioisotope, 2017–2031
13.2.1. Technetium-99
13.2.2. Gallium-68
13.2.3. Iodine-131
13.2.4. Iodine-123
13.2.5. 18F
13.2.6. Y-90
13.2.7. Lutetium (Lu) 177
13.2.8. Copper (Cu) 67
13.2.9. Copper (Cu) 64
13.2.10. Others
13.3. Market Value Forecast, by Application, 2017–2031
13.3.1. Oncology
13.3.2. Cardiology
13.3.3. Others
13.4. Market Value Forecast, by Source, 2017–2031
13.4.1. Nuclear Reactors
13.4.2. Cyclotrons
13.5. Market Value Forecast, by Approach, 2017–2031
13.5.1. Targeted Therapeutic (Rx)
13.5.2. Companion Diagnostic (DX)
13.6. Market Value Forecast, by End-user, 2017–2031
13.6.1. Hospitals
13.6.2. Academic & Research Institutes
13.6.3. Others
13.7. Market Value Forecast, by Country/Sub-region, 2017–2031
13.7.1. Germany
13.7.2. U.K.
13.7.3. France
13.7.4. Italy
13.7.5. Spain
13.7.6. Rest of Europe
13.8. Market Attractiveness Analysis
13.8.1. By Radioisotope
13.8.2. By Application
13.8.3. By Source
13.8.4. By Approach
13.8.5. By End-user
13.8.6. By Country/Sub-region
14. Asia Pacific Radiopharmaceutical Theranostics Market Analysis and Forecast
14.1. Introduction
14.1.1. Key Findings
14.2. Market Value Forecast, by Radioisotope, 2017–2031
14.2.1. Technetium-99
14.2.2. Gallium-68
14.2.3. Iodine-131
14.2.4. Iodine-123
14.2.5. 18F
14.2.6. Y-90
14.2.7. Lutetium (Lu) 177
14.2.8. Copper (Cu) 67
14.2.9. Copper (Cu) 64
14.2.10. Others
14.3. Market Value Forecast, by Application, 2017–2031
14.3.1. Oncology
14.3.2. Cardiology
14.3.3. Others
14.4. Market Value Forecast, by Source, 2017–2031
14.4.1. Nuclear Reactors
14.4.2. Cyclotrons
14.5. Market Value Forecast, by Approach, 2017–2031
14.5.1. Targeted Therapeutic (Rx)
14.5.2. Companion Diagnostic (DX)
14.6. Market Value Forecast, by End-user, 2017–2031
14.6.1. Hospitals
14.6.2. Academic & Research Institutes
14.6.3. Others
14.7. Market Value Forecast, by Country/Sub-region, 2017–2031
14.7.1. Japan
14.7.2. China
14.7.3. India
14.7.4. Australia & New Zealand
14.7.5. Rest of Asia Pacific
14.8. Market Attractiveness Analysis
14.8.1. By Radioisotope
14.8.2. By Application
14.8.3. By Source
14.8.4. By Approach
14.8.5. By End-user
14.8.6. By Country/Sub-region
15. Latin America Radiopharmaceutical Theranostics Market Analysis and Forecast
15.1. Introduction
15.1.1. Key Findings
15.2. Market Value Forecast By Radioisotope, 2017–2031
15.2.1. Technetium-99
15.2.2. Gallium-68
15.2.3. Iodine-131
15.2.4. Iodine-123
15.2.5. 18F
15.2.6. Y-90
15.2.7. Lutetium (Lu) 177
15.2.8. Copper (Cu) 67
15.2.9. Copper (Cu) 64
15.2.10. Others
15.3. Market Value Forecast, by Application, 2017–2031
15.3.1. Oncology
15.3.2. Cardiology
15.3.3. Others
15.4. Market Value Forecast, by Source, 2017–2031
15.4.1. Nuclear Reactors
15.4.2. Cyclotrons
15.5. Market Value Forecast, by Approach, 2017–2031
15.5.1. Targeted Therapeutic (Rx)
15.5.2. Companion Diagnostic (DX)
15.6. Market Value Forecast, by End-user, 2017–2031
15.6.1. Hospitals
15.6.2. Academic & Research Institutes
15.6.3. Others
15.7. Market Value Forecast, by Country/Sub-region, 2017–2031
15.7.1. Brazil
15.7.2. Mexico
15.7.3. Rest of Latin America
15.8. Market Attractiveness Analysis
15.8.1. By Radioisotope
15.8.2. By Application
15.8.3. By Source
15.8.4. By Approach
15.8.5. By End-user
15.8.6. By Country/Sub-region
16. Middle East & Africa Radiopharmaceutical Theranostics Market Analysis and Forecast
16.1. Introduction
16.1.1. Key Findings
16.2. Market Value Forecast, by Radioisotope, 2017–2031
16.2.1. Technetium-99
16.2.2. Gallium-68
16.2.3. Iodine-131
16.2.4. Iodine-123
16.2.5. 18F
16.2.6. Y-90
16.2.7. Lutetium (Lu) 177
16.2.8. Copper (Cu) 67
16.2.9. Copper (Cu) 64
16.2.10. Others
16.3. Market Value Forecast, by Application, 2017–2031
16.3.1. Oncology
16.3.2. Cardiology
16.3.3. Others
16.4. Market Value Forecast, by Source, 2017–2031
16.4.1. Nuclear Reactors
16.4.2. Cyclotrons
16.5. Market Value Forecast, by Approach, 2017–2031
16.5.1. Targeted Therapeutic (Rx)
16.5.2. Companion Diagnostic (DX)
16.6. Market Value Forecast, by End-user, 2017–2031
16.6.1. Hospitals
16.6.2. Academic & Research Institutes
16.6.3. Others
16.7. Market Value Forecast, by Country/Sub-region, 2017–2031
16.7.1. GCC Countries
16.7.2. South Africa
16.7.3. Rest of Middle East & Africa
16.8. Market Attractiveness Analysis
16.8.1. By Radioisotope
16.8.2. By Application
16.8.3. By Source
16.8.4. By Approach
16.8.5. By End-user
16.8.6. By Country/Sub-region
17. Competition Landscape
17.1. Market Player - Competition Matrix (by tier and size of companies)
17.2. Company Profiles
17.2.1. Nihon Medi-Physics
17.2.1.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.1.2. Company Financials
17.2.1.3. Growth Strategies
17.2.1.4. SWOT Analysis
17.2.2. ITM Isotopen Technologien München AG
17.2.2.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.2.2. Company Financials
17.2.2.3. Growth Strategies
17.2.2.4. SWOT Analysis
17.2.3. Advanced Accelerator Applications
17.2.3.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.3.2. Company Financials
17.2.3.3. Growth Strategies
17.2.3.4. SWOT Analysis
17.2.4. Telix Pharmaceuticals
17.2.4.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.4.2. Company Financials
17.2.4.3. Growth Strategies
17.2.4.4. SWOT Analysis
17.2.5. GE Healthcare
17.2.5.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.5.2. Company Financials
17.2.5.3. Growth Strategies
17.2.5.4. SWOT Analysis
17.2.6. Theragnostics Ltd
17.2.6.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.6.2. Company Financials
17.2.6.3. Growth Strategies
17.2.6.4. SWOT Analysis
17.2.7. NuView Life Sciences
17.2.7.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.7.2. Company Financials
17.2.7.3. Growth Strategies
17.2.7.4. SWOT Analysis
17.2.8. Jubilant Pharma Limited
17.2.8.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.8.2. Company Financials
17.2.8.3. Growth Strategies
17.2.8.4. SWOT Analysis
17.2.9. Lantheus Holdings, Inc.
17.2.9.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.9.2. Company Financials
17.2.9.3. Growth Strategies
17.2.9.4. SWOT Analysis
17.2.10. Curium Pharma
17.2.10.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.10.2. Company Financials
17.2.10.3. Growth Strategies
17.2.10.4. SWOT Analysis
17.2.11. Bayer AG
17.2.11.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.11.2. Company Financials
17.2.11.3. Growth Strategies
17.2.11.4. SWOT Analysis
17.2.12. Clarity Pharmaceuticals
17.2.12.1. Company Overview (HQ, Business Segments, Employee Strength)
17.2.12.2. Company Financials
17.2.12.3. Growth Strategies
17.2.12.4. SWOT Analysis
List of Tables
Table 01: FDA Approved Radiopharmaceuticals Products
Table 02: FDA Approved Radiopharmaceuticals Products
Table 03: FDA Approved Radiopharmaceuticals Products
Table 04: Radiopharmaceuticals used in diagnostic applications along with their important physical properties
Table 05: Radiopharmaceuticals used in therapeutic applications along with their important physical properties
Table 06: List of Current and Future Radiopharmaceutical Theranostics Pairs
Table 07: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 08: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 09: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 10: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 11: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 12: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Region, 2017–2031
Table 13: North America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country, 2017–2031
Table 14: North America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 15: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 16: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 17: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 18: North America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 19: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 20: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 21: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 22: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 23: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 24: Europe Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 25: Asia Pacific Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 26: Asia Pacific Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 27: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 28: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 29: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 30: Asia Pacific Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 31: Latin America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 32: Latin America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 33: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 34: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 35: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 36: Latin America Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
Table 37: Middle East & Africa Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Country/Sub-region, 2017–2031
Table 38: Middle East & Africa Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, by Radioisotope, 2017–2031
Table 39: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Application, 2017–2031
Table 40: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Source, 2017–2031
Table 41: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by Approach, 2017–2031
Table 42: Middle East & Africa Radiopharmaceutical Theranostics Market Revenue (US$ Mn) Forecast, by End-user, 2017–2031
List of Figures
Figure 01: Global Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast and Y-o-Y Growth (%) Projection, 2017–2031
Figure 02: Global Radiopharmaceutical Theranostics Market Value Share, by Region, 2020
Figure 03: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031
Figure 04: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031
Figure 05: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Technetium-99, 2017–2031
Figure 06: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Gallium-68 , 2017–2031
Figure 07: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Iodine-131, 2017–2031
Figure 08: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Iodine-123, 2017–2031
Figure 09: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by 18F , 2017–2031
Figure 10: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Y-90, 2017–2031
Figure 11: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Lutetium (Lu) 177, 2017–2031
Figure 12: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Copper (Cu) 67, 2017–2031
Figure 13: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Copper (Cu) 64, 2017–2031
Figure 14: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017–2031
Figure 15: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031
Figure 16: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031
Figure 17: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Oncology, 2017–2031
Figure 18: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cardiology, 2017–2031
Figure 19: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017–2031
Figure 20: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031
Figure 21: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031
Figure 22: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Nuclear Reactors, 2017–2031
Figure 23: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Cyclotrons, 2017–2031
Figure 24: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031
Figure 25: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031
Figure 26: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Targeted Therapeutic (Rx), 2017–2031
Figure 27: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Companion Diagnostic (DX), 2017–2031
Figure 28: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031
Figure 29: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031
Figure 30: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Hospitals, 2017–2031
Figure 31: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Academic & Research Institutes, 2017–2031
Figure 32: Global Radiopharmaceutical Theranostics Market Revenue (US$ Mn), by Others, 2017–2031
Figure 33: Global Radiopharmaceutical Theranostics Market Value Share Analysis, by Region, 2020 and 2031
Figure 34: Global Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Region, 2021–2031
Figure 35: North America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 36: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Country, 2020 and 2031
Figure 37: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country, 2021–2031
Figure 38: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031
Figure 39: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031
Figure 40: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031
Figure 41: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031
Figure 42: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031
Figure 43: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031
Figure 44: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031
Figure 45: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031
Figure 46: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031
Figure 47: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031
Figure 48: Europe Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 49: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 50: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 51: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031
Figure 52: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031
Figure 53: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031
Figure 54: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031
Figure 55: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031
Figure 56: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031
Figure 57: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031
Figure 58: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031
Figure 59: Europe Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031
Figure 60: Europe Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031
Figure 61: Asia Pacific Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 62: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 63: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 64: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031
Figure 65: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031
Figure 66: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031
Figure 67: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031
Figure 68: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031
Figure 69: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031
Figure 70: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031
Figure 71: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031
Figure 72: Asia Pacific Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031
Figure 73: Asia Pacific Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031
Figure 74: Latin America Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 75: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 76: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 77: North America Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031
Figure 78: North America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031
Figure 79: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031
Figure 80: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031
Figure 81: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031
Figure 82: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031
Figure 83: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031
Figure 84: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031
Figure 85: Latin America Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031
Figure 86: Latin America Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031
Figure 87: Middle East & Africa Radiopharmaceutical Theranostics Market Value (US$ Mn) Forecast, 2017–2031
Figure 88: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Country/Sub-region, 2020 and 2031
Figure 89: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Country/Sub-region, 2021–2031
Figure 90: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Radioisotope, 2020 and 2031
Figure 91: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Radioisotope, 2021–2031
Figure 92: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Application, 2020 and 2031
Figure 93: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Application, 2021–2031
Figure 94: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Source, 2020 and 2031
Figure 95: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Source, 2021–2031
Figure 96: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by Approach, 2020 and 2031
Figure 97: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by Approach, 2021–2031
Figure 98: Middle East & Africa Radiopharmaceutical Theranostics Market Value Share Analysis, by End-user, 2020 and 2031
Figure 99: Middle East & Africa Radiopharmaceutical Theranostics Market Attractiveness Analysis, by End-user, 2021–2031
Complete the form below and we'll get back to you shortly.
Copyright © Transparency Market Research, Inc. All Rights reserved
Trust Online
